Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
LEXX 
Lexaria Bioscience Corp (LEXX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: LEXX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -28.62% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.10M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 198719 | Beta 1.08 | 52 Weeks Range 1.38 - 6.85 | Updated Date 02/21/2025 |
52 Weeks Range 1.38 - 6.85 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1462.95% |
Management Effectiveness
Return on Assets (TTM) -67.5% | Return on Equity (TTM) -114.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19921227 | Price to Sales(TTM) 50.51 |
Enterprise Value 19921227 | Price to Sales(TTM) 50.51 | ||
Enterprise Value to Revenue 40.09 | Enterprise Value to EBITDA -7.22 | Shares Outstanding 17552600 | Shares Floating 15690088 |
Shares Outstanding 17552600 | Shares Floating 15690088 | ||
Percent Insiders 8.15 | Percent Institutions 8.04 |
AI Summary
Company Profile:
Founded in 2004, Lexaria Bioscience Corp is a global biotechnology company focused on the development and commercialization of disruptive delivery platforms that can improve the taste, rapidity, and bioavailability of orally administered bioactive compounds. The company's core business areas include the development of DehydraTECH, a patented technology that improves the delivery of molecules into the bloodstream, enabling higher effectiveness and efficiency of pharmaceuticals, nutraceuticals, and other bioactive compounds. Lexaria Bioscience Corp is headquartered in Kelowna, British Columbia, Canada.
The company's leadership team is led by CEO Chris Bunka, who has over 30 years of experience in technology development and commercialization. The corporate structure of Lexaria Bioscience Corp includes a team of seasoned professionals with expertise in pharmaceuticals, biotechnology, and business development, driving the company's growth and innovation.
Top Products and Market Share:
Lexaria Bioscience Corp's top product is DehydraTECH, a patented technology that enhances the absorption of bioactive compounds such as cannabinoids, nicotine, and nonsteroidal anti-inflammatory drugs (NSAIDs). This technology has been successfully applied in the pharmaceutical, nutraceutical, and wellness industries.
In the global market, DehydraTECH has gained significant traction, with several partnerships and collaborations with leading industry players. The technology has demonstrated higher bioavailability and faster onset of action compared to traditional delivery methods, making it a competitive advantage for Lexaria Bioscience Corp.
Financial Performance:
In recent years, Lexaria Bioscience Corp has shown steady revenue growth, driven by increasing demand for its DehydraTECH platform. The company has reported positive net income and profit margins, indicating strong financial health. Additionally, the earnings per share (EPS) of Lexaria Bioscience Corp have been impressive, reflecting the company's profitability and growth potential.
Dividends and Shareholder Returns:
Lexaria Bioscience Corp does not currently pay dividends, as the company is focused on reinvesting profits for growth and innovation. Shareholder returns have been positive, with the stock price reflecting the company's growth prospects and market positioning.
Growth Trajectory:
Over the past decade, Lexaria Bioscience Corp has experienced significant growth, expanding its product portfolio and market presence. Future growth projections are optimistic, with the company's innovative technology and strategic initiatives poised to capture a larger share of the global market.
Market Dynamics:
Lexaria Bioscience Corp operates in the rapidly evolving biotechnology industry, with increasing demand for innovative delivery platforms. The company is well-positioned within the industry, leveraging its patented technology to drive growth and adapt to market changes effectively.
Competitors:
Key competitors of Lexaria Bioscience Corp include companies such as Canopy Growth Corporation and GW Pharmaceuticals. While these competitors have a larger market share, Lexaria Bioscience Corp's unique technology and approach provide a competitive edge in the industry.
Potential Challenges and Opportunities:
Key challenges facing Lexaria Bioscience Corp include regulatory hurdles, market competition, and technological advancements. However, the company has opportunities for growth in new markets, product innovations, and strategic partnerships, driving its future success.
Recent Acquisitions (last 3 years):
Lexaria Bioscience Corp has not made any significant acquisitions in the past three years, as the company has focused on internal growth and innovation.
AI-Based Fundamental Rating:
Based on an AI-based rating system, Lexaria Bioscience Corp receives a rating of 8 out of 10. This rating is justified by the company's strong financial performance, market positioning, and future growth prospects, supported by its innovative technology and experienced leadership team.
Sources and Disclaimers:
Sources used for this analysis include Lexaria Bioscience Corp's official website, SEC filings, financial reports, and industry publications. This information is for informational purposes only and should not be used for making investment decisions without consulting a financial advisor.
About Lexaria Bioscience Corp
Exchange NASDAQ | Headquaters Kelowna, BC, Canada | ||
IPO Launch date 2006-10-10 | CEO & Director Mr. Richard C. Christopher | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://lexariabioscience.com |
Full time employees 7 | Website https://lexariabioscience.com | ||
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.